On January 23, 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, reported that Dr. Simon Woodcock, Vice President, Oncology at Redx Pharma, will present at the 2nd Annual Wnt & β-Catenin Pathway Targeted Drug Development Summit (24-26 January, Boston, MA) (Press release, Redx Pharma, JAN 23, 2023, View Source [SID1234626464]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the presentation, which will take place on Thursday 26 January at 10:30 (EST), Dr. Woodcock will discuss the challenges of genetic selection in defined patient populations and how this relates directly to Wnt/β-Catenin Biomarkers in patient selection for clinical studies of targeted therapies, such as Redx’s RXC004.

RXC004 is a clinical stage, highly potent and selective, orally active Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand dependent cancer. It is currently being evaluated in Phase 2 proof-of-concept clinical studies as a monotherapy and in combination with anti-PD-1, Nivolumab, in genetically selected metastatic colorectal cancer (MSS mCRC) (clinicaltrials.gov NCT04907539), as monotherapy in genetically selected pancreatic cancer, and as a monotherapy and in combination with anti-PD-1, Pembrolizumab, in biliary tract cancers (clinicaltrials.gov NCT04907851).